About us
Browse:
Our mission
Leadership
Our story
Contact Moderna
tab2
Find information about our leadership team, Board of Directors and our commitment to diversity.
49%
Of our team identify as women *2023
45%
Of our team identify as racially or ethnically diverse *U.S. 2023
39%
Of our leadership team identify as women *2023
Diversity at Moderna
We are creating an inclusive and diverse working environment that encourages and rewards curiosity, collaboration and agility.
Meet our executive team
- text-center
Stéphane Bancel
Chief Executive Officer
linkedin
Stéphane Bancel has been Moderna's Chief Executive Officer since October 2011 and has served on Moderna’s board of directors since March 2011. Prior to joining Moderna, Mr. Bancel was the Chief Executive Officer of the French diagnostics company bioMérieux SA for five years. From July 2000 to March 2006, he held various positions at Eli Lilly and Company, including Managing Director, Belgium, and Executive Director, Global Manufacturing Strategy and Supply Chain. Before his tenure at Eli Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
In addition to his role at Moderna, Mr. Bancel is a board member of Generate:Biomedicines and a Venture Partner at Flagship Pioneering. He holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School
Mr. Bancel was nominated Chevalier of the Legion d'honneur in 2022, the highest recognition in France, and was elected to the U.S. National Academy of Engineering in 2024.
In addition to his role at Moderna, Mr. Bancel is a board member of Generate:Biomedicines and a Venture Partner at Flagship Pioneering. He holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School
Mr. Bancel was nominated Chevalier of the Legion d'honneur in 2022, the highest recognition in France, and was elected to the U.S. National Academy of Engineering in 2024.
default
Stephen Hoge, M.D.
President
linkedin
Stephen Hoge, M.D., serves as President of Moderna, where he oversees Research & Development, Manufacturing and Commercial for the Company's three franchises: Infectious Disease Vaccines, Individualized Neoantigen Therapy (INT), and Rare Disease Therapeutics. As President, Dr. Hoge also plays a central role in defining Moderna's corporate strategy, shaping its overall pipeline, and driving operational execution. In his more than 13 years at the Company, Dr. Hoge has led the build of most functions, including Research, Development, Medical and Commercial. He joined Moderna in 2012 from McKinsey & Company, where he was a partner in the healthcare practice. Prior to McKinsey, Dr. Hoge was a resident physician in New York City. He holds a B.A. in Neuroscience from Amherst College, and an M.D. from the University of California, San Francisco.
default
- text-center
Ester Banque
Chief Commercial Officer
As Chief Commercial Officer, Ester Banque leads Moderna’s commercial organization.
Ms. Banque brings more than 30 years of commercial leadership experience across biopharmaceuticals and animal health. Most recently, she served as Executive Vice President and President, U.S. Operations at Zoetis, where she led the company’s largest market and oversaw its U.S. commercial operations. Prior to Zoetis, she was Senior Vice President and General Manager of Bristol Myers Squibb’s U.S. Hematology & Cell Therapy Business, where she accelerated the launch of five new products. Before joining Bristol Myers Squibb, Ms. Banque spent 25 years at Novartis in leadership roles across multiple therapeutic areas and geographies, including leading the Europe and U.S. commercialization of one of the company’s most successful launches and serving as General Manager, Oncology, Germany.
Ms. Banque earned a Bachelor of Science in Chemistry from Universitat Autònoma de Barcelona and a Master of Business Administration from Universitat Pompeu Fabra in Spain.
default
David Berman, M.D., Ph.D.
Chief Development Officer
As Chief Development Officer, David Berman, M.D., Ph.D., leads Moderna’s development organization.
Dr. Berman brings more than two decades of experience advancing immunotherapies across oncology and infectious disease. He has worked on more than a dozen clinical-stage programs and held senior leadership roles in the development of four globally approved oncology biologics. Most recently, he served as Executive Vice President and Head of Research and Development at Immunocore, where he led the development and approval of the first T cell receptor therapeutic. Prior to Immunocore, Dr. Berman was Senior Vice President and Head of AstraZeneca’s Immuno-oncology franchise. He also held senior development roles at Bristol-Myers Squibb, including Global Clinical Lead for the first approved immune checkpoint inhibitor.
Dr. Berman earned his M.D. and Ph.D. from the University of Texas Southwestern Medical School. He completed his pathology training at the National Cancer Institute and a fellowship at The Johns Hopkins Hospital.
Dr. Berman brings more than two decades of experience advancing immunotherapies across oncology and infectious disease. He has worked on more than a dozen clinical-stage programs and held senior leadership roles in the development of four globally approved oncology biologics. Most recently, he served as Executive Vice President and Head of Research and Development at Immunocore, where he led the development and approval of the first T cell receptor therapeutic. Prior to Immunocore, Dr. Berman was Senior Vice President and Head of AstraZeneca’s Immuno-oncology franchise. He also held senior development roles at Bristol-Myers Squibb, including Global Clinical Lead for the first approved immune checkpoint inhibitor.
Dr. Berman earned his M.D. and Ph.D. from the University of Texas Southwestern Medical School. He completed his pathology training at the National Cancer Institute and a fellowship at The Johns Hopkins Hospital.
default
Jerh Collins, Ph.D.
Chief Technical Operations and Quality Officer
linkedin
As Chief Technical Operations and Quality Officer, Dr. Collins is responsible for the technical development, quality, and supply of preclinical, clinical and commercial programs within Moderna’s portfolio.
Dr. Collins joined Moderna from Novartis, where he held roles of increasing responsibility over the last nearly 30 years, focused on pharmaceutical production and manufacturing, including roles serving as Head of Global Chemical Operations and Anti-Infectives and as Head of Global Chemical Operations.
Dr. Collins received his Bachelor of Science in Chemistry and his Ph.D. in Organic Chemistry from University College Cork, Ireland. He also conducted post-doctoral cancer research at Arizona State University.
Dr. Collins joined Moderna from Novartis, where he held roles of increasing responsibility over the last nearly 30 years, focused on pharmaceutical production and manufacturing, including roles serving as Head of Global Chemical Operations and Anti-Infectives and as Head of Global Chemical Operations.
Dr. Collins received his Bachelor of Science in Chemistry and his Ph.D. in Organic Chemistry from University College Cork, Ireland. He also conducted post-doctoral cancer research at Arizona State University.
default
Tracey Franklin
Chief People and Digital Technology Officer
linkedin
As Chief People and Digital Technology Officer, Tracey Franklin leads Moderna’s talent and digital organizations.
Before taking on her expanded role, Ms. Franklin served as Chief Human Resources Officer of Moderna from 2019 to 2024, leading the Company’s people strategy, culture and workforce capabilities to support rapid growth and innovation through the COVID-19 pandemic. Under her leadership, Moderna expanded its workforce from approximately 800 to nearly 6,000 employees globally.
She joined Moderna following 15 years at Merck & Co., Inc. where she led Merck’s global talent strategy as Vice President, HR Chief Talent and Strategy Officer and served on Merck’s HR Leadership Team. Ms. Franklin’s previous leadership roles included responsibility for HR for all divisions in the European region, head of HR for the U.K. and Ireland subsidiaries of Merck, and HR Operations leader responsible for HR program implementation across Merck’s global footprint. She was based in Switzerland, the U.K. and the U.S.
Ms. Franklin holds a Bachelor of Arts in communication arts and sciences from Pennsylvania State University and a Master of Arts in industrial and organizational psychology from Fairleigh Dickinson University.
Before taking on her expanded role, Ms. Franklin served as Chief Human Resources Officer of Moderna from 2019 to 2024, leading the Company’s people strategy, culture and workforce capabilities to support rapid growth and innovation through the COVID-19 pandemic. Under her leadership, Moderna expanded its workforce from approximately 800 to nearly 6,000 employees globally.
She joined Moderna following 15 years at Merck & Co., Inc. where she led Merck’s global talent strategy as Vice President, HR Chief Talent and Strategy Officer and served on Merck’s HR Leadership Team. Ms. Franklin’s previous leadership roles included responsibility for HR for all divisions in the European region, head of HR for the U.K. and Ireland subsidiaries of Merck, and HR Operations leader responsible for HR program implementation across Merck’s global footprint. She was based in Switzerland, the U.K. and the U.S.
Ms. Franklin holds a Bachelor of Arts in communication arts and sciences from Pennsylvania State University and a Master of Arts in industrial and organizational psychology from Fairleigh Dickinson University.
default
Shannon Thyme Klinger
Chief Legal Officer and Corporate Secretary
linkedin
As Chief Legal Officer and Corporate Secretary, Shannon Thyme Klinger leads Moderna’s legal, governance and corporate compliance efforts.
Ms. Klinger joined Moderna from Novartis (NYSE: NVS), where she served as Chief Legal Officer and a member of the Novartis Executive Committee since 2018. Previously, she served as Chief Ethics, Risk & Compliance Officer. During her ten-year tenure at Novartis, she held other roles of increasing responsibility, including as Chief Ethics and Compliance Officer and Global Head of Litigation, General Counsel and Global Head of Legal at Sandoz, a Novartis division.
Across her career, Ms. Klinger’s work has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, championing the responsible use of data, and enabling excellence in product launches. She is also a committed advocate for diversity, equity and inclusion.
Ms. Klinger served on the board of directors of the SIX Group in Switzerland from 2016 to 2020.
Ms. Klinger received her Juris Doctorate with honors from the University of North Carolina at Chapel Hill and a bachelor’s degree in psychology from the University of Notre Dame. She is a member of the State Bar of Georgia and the District of Columbia Bar.
Ms. Klinger joined Moderna from Novartis (NYSE: NVS), where she served as Chief Legal Officer and a member of the Novartis Executive Committee since 2018. Previously, she served as Chief Ethics, Risk & Compliance Officer. During her ten-year tenure at Novartis, she held other roles of increasing responsibility, including as Chief Ethics and Compliance Officer and Global Head of Litigation, General Counsel and Global Head of Legal at Sandoz, a Novartis division.
Across her career, Ms. Klinger’s work has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, championing the responsible use of data, and enabling excellence in product launches. She is also a committed advocate for diversity, equity and inclusion.
Ms. Klinger served on the board of directors of the SIX Group in Switzerland from 2016 to 2020.
Ms. Klinger received her Juris Doctorate with honors from the University of North Carolina at Chapel Hill and a bachelor’s degree in psychology from the University of Notre Dame. She is a member of the State Bar of Georgia and the District of Columbia Bar.
default
Rose Loughlin, Ph.D.
Executive Vice President, Research
As EVP of Research, Rose Loughlin, Ph.D., leads Moderna's platform science and therapeutics research organization, focusing on pioneering scientific advancements and further strengthening the Company’s innovative pipeline.
Dr. Loughlin previously served as Senior Vice President of Research and Early Development at Moderna, where she played a crucial role in advancing the Company's portfolio and platform strategy since joining in 2016. Before joining Moderna, Dr. Loughlin held roles at Biogen in business development and at L.E.K. Consulting, where she contributed to defining corporate and portfolio growth strategies for biopharmaceutical companies. Dr. Loughlin holds a Ph.D. in Biophysics from the University of California, Berkeley, and a Bachelor of Arts in physics from Harvard University.
Dr. Loughlin previously served as Senior Vice President of Research and Early Development at Moderna, where she played a crucial role in advancing the Company's portfolio and platform strategy since joining in 2016. Before joining Moderna, Dr. Loughlin held roles at Biogen in business development and at L.E.K. Consulting, where she contributed to defining corporate and portfolio growth strategies for biopharmaceutical companies. Dr. Loughlin holds a Ph.D. in Biophysics from the University of California, Berkeley, and a Bachelor of Arts in physics from Harvard University.
default
Jamey Mock
Chief Financial Officer
linkedin
As Chief Financial Officer, Jamey Mock oversees financial, business development and business services functions at Moderna.
Mr. Mock previously served as Senior Vice President and CFO of PerkinElmer, Inc., a life sciences, diagnostics and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the United States and overseas.
Mr. Mock holds a Bachelor of Arts in economics from St. Lawrence University.
Mr. Mock previously served as Senior Vice President and CFO of PerkinElmer, Inc., a life sciences, diagnostics and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the United States and overseas.
Mr. Mock holds a Bachelor of Arts in economics from St. Lawrence University.
default
Environment
h2
We believe that it is our responsibility to grow our company in a way that protects the planet and minimizes our impact on the environment.
left
secondary
normal
Net-0
carbon emissions by 2030 (Scopes 1 & 2)
100%
subsidized green transportation across our campuses in the US